Brain Res Bull
Promotional first-month pricing is common, so confirm ongoing cost
FDA applies four factors to determine whether a compounded drug is essentially a copy of a commercially available product: Same active ingredient semaglutide or tirzepatide Same route of administration subcutaneous injection Same dosage form injectable solution Same strength matching FDA-approved doses (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, etc.) If your compounded product meets these four criteria, it is essentially a copy of Ozempic, Wegovy, Mounjaro, or Zepbound and it is illegal to compound, prescribe, or dispense
Despite the rapid development of intravenous, subcutaneous or intramuscular injection, oral drug delivery is still considered to be the preferred route in terms of good compliance and ease of administration (McConville, 2017